High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab

BACKGROUND: Increased levels of cytokines, including interleukin-6 (IL-6), reflect inflammation and have been shown to be predictive of therapeutic responses, fatigue, pain, and depression in patients with rheumatoid arthritis (RA), but limited data exist on associations between IL-6 levels and heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Boklage, Susan H., Kimura, Toshio, Joly, Florence, Boyapati, Anita, Msihid, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574446/
https://www.ncbi.nlm.nih.gov/pubmed/33081825
http://dx.doi.org/10.1186/s13075-020-02344-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574446/
https://www.ncbi.nlm.nih.gov/pubmed/33081825
http://dx.doi.org/10.1186/s13075-020-02344-3

Ejemplares similares